A Study of MabThera/Rituxan (Rituximab) in Patients With Follicular Non-Hodgkin's Lymphoma
Status:
Completed
Trial end date:
2004-04-01
Target enrollment:
Participant gender:
Summary
This single-arm, open-label, multi-centre study will evaluate the efficacy and safety of
MabThera/Rituxan (rituximab) in patients with follicular non-Hodgkin's lymphoma with minimal
residual disease after autologous haematopoietic stem cell transplantation (bone marrow or
peripheral blood). Two groups of patients will be considered for treatment. Group A: Patients
with evaluable minimal tumor mass, Group B: Patients with complete response and abnormal
B-cell lymphoma 2 (bcl2) status. Patients will receive MabThera/Rituxan 375 mg/m2
intravenously once every week. The anticipated time on study treatment is 4 weeks.